Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is broadly based on three types of treatments: cDMARDs (e.g., methotrexate, leflunomide); biological DMARDs (TNF-α inhibitors, anti-CD20 MAbs, IL-6 inhibitors, and selective costimulation inhibitors); and JAK inhibitors. TNF-α inhibitors are the most widely prescribed targeted therapies for RA patients refractory to conventional DMARDs, while other biologics and JAK inhibitors largely compete for share of TNF-α-inhibitor-refractory patients. The approval of cost-effective biosimilars and the incorporation of several therapies into China’s National Reimbursement Drug List have improved patient access to these premium-priced therapies. In this report, we explore how unmet need, pricing, coverage, and regulatory reforms in the A&R landscape of China will likely impact the success of current and future players in this highly lucrative market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys of 50 rheumatologists
Diagnosed and drug-treated prevalence of rheumatoid arthritis (RA) in China, with urban and rural breakup; 12-month total and diagnosed prevalence of RA by severity
10-year, annualized, drug-level sales and patient share of key RA therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions
Phase 3/PR: 10+ drugs; Phase 2: 5+ drugs; coverage of select preclinical and Phase 1 products